Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

1.

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.

PMID:
23090078
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.

Yang S, Dudley ME, Rosenberg SA, Morgan RA.

J Immunother. 2010 Jul-Aug;33(6):648-58. doi: 10.1097/CJI.0b013e3181e311cb.

PMID:
20551831
[PubMed - indexed for MEDLINE]
3.

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR.

Blood. 2012 Jan 5;119(1):72-82. doi: 10.1182/blood-2011-07-366419. Epub 2011 Oct 26.

PMID:
22031866
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.

Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ, Peinert S, Smyth MJ, Trapani JA, Kershaw MH, Darcy PK, Ritchie DS.

Gene Ther. 2010 Sep;17(9):1105-16. doi: 10.1038/gt.2010.59. Epub 2010 Apr 29.

PMID:
20428216
[PubMed - indexed for MEDLINE]
5.

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.

Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC.

Blood. 2011 Feb 10;117(6):1888-98. doi: 10.1182/blood-2010-10-310599. Epub 2010 Dec 1.

PMID:
21123821
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC.

Blood. 2005 Feb 15;105(4):1622-31. Epub 2004 Oct 26.

PMID:
15507526
[PubMed - indexed for MEDLINE]
Free Article
7.

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.

Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X.

Hum Gene Ther. 2010 Jan;21(1):75-86. doi: 10.1089/hum.2009.122.

PMID:
19719389
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R.

Cancer Res. 2011 Apr 15;71(8):2871-81. doi: 10.1158/0008-5472.CAN-10-0552. Epub 2011 Apr 12.

PMID:
21487038
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.

PMID:
17108138
[PubMed - indexed for MEDLINE]
Free Article
10.

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ.

Cancer Res. 2011 May 15;71(10):3516-27. doi: 10.1158/0008-5472.CAN-10-3843. Epub 2011 May 10. Erratum in: Cancer Res. 2011 Jul 1;71(13):4734.

PMID:
21558388
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.

J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138.

PMID:
19561539
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.

PMID:
23791878
[PubMed - indexed for MEDLINE]
13.

Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors.

Lerret NM, Rogozinska M, Jaramillo A, Marzo AL.

PLoS One. 2012;7(7):e41240. doi: 10.1371/journal.pone.0041240. Epub 2012 Jul 20.

PMID:
22911764
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Simplified process for the production of anti-CD19-CAR-engineered T cells.

Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, Wayne A, Sabatino M.

Cytotherapy. 2013 Nov;15(11):1406-15. doi: 10.1016/j.jcyt.2013.06.003. Epub 2013 Aug 28.

PMID:
23992830
[PubMed - indexed for MEDLINE]
15.

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Leukemia. 2010 Jun;24(6):1160-70. doi: 10.1038/leu.2010.75. Epub 2010 Apr 29.

PMID:
20428207
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.

Kaka AS, Shaffer DR, Hartmaier R, Leen AM, Lu A, Bear A, Rooney CM, Foster AE.

J Immunother. 2009 Sep;32(7):726-36. doi: 10.1097/CJI.0b013e3181ad4071. Erratum in: J Immunother. 2009 Nov-Dec;32(9):919. Hartmeier, Ryan [corrected to Hartmaier, Ryan].

PMID:
19561536
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Kaiser AD, Gadiot J, Guislain A, Blank CU.

Cancer Immunol Immunother. 2013 Mar;62(3):503-15. doi: 10.1007/s00262-012-1350-1. Epub 2012 Sep 23.

PMID:
23001162
[PubMed - indexed for MEDLINE]
18.

Treatment of advanced leukemia in mice with mRNA engineered T cells.

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.

Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.

PMID:
21838572
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Simultaneous assessment of antigen-stimulated cytokine production and memory subset composition of memory CD8 T cells.

Jabbari A, Harty JT.

J Immunol Methods. 2006 Jun 30;313(1-2):161-8. Epub 2006 May 26.

PMID:
16762359
[PubMed - indexed for MEDLINE]
20.

Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.

Cheadle EJ, Sheard V, Rothwell DG, Bridgeman JS, Ashton G, Hanson V, Mansoor AW, Hawkins RE, Gilham DE.

J Immunol. 2014 Apr 15;192(8):3654-65. doi: 10.4049/jimmunol.1302148. Epub 2014 Mar 12.

PMID:
24623129
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk